Boosting Responses to Neoadjuvant Therapy in Resectable NSCLC Multi-drug platform study identifies promising durvalumab-based combinations Apr 12, 2022
Neoadjuvant Nivolumab a 'New Standard' in Lung Cancer "Another quantum leap in lung cancer therapy," expert says Apr 12, 2022
Longer-Term Sotorasib Data 'Encouraging' in KRAS-Mutated NSCLC Prolonged tumor response seen in 2-year analysis Apr 11, 2022
More Research Needed on Use of Premium Cigars, Report Finds These cigars seem less dangerous than cigarettes -- but it's only because of how they are smoked Mar 10, 2022
Cancer May Heighten Odds of Guillain-Barre Syndrome Link strongest with hematologic malignancies as well as prostate, breast, and respiratory cancers Mar 03, 2022
ARB-Cancer Link May Come Down to Cumulative Exposure Does a new paper resolve the conflicting safety data on the popular antihypertensives? Mar 02, 2022
Early Clinical Activity With CDK4/6 Inhibitor in Pretreated Mesothelioma Disease control in 54% of patients in first clinical evaluation of abemaciclib Feb 17, 2022
Long-Term Survival Benefit in NSCLC With Another Anti-PD-1/L1 Drug Significant improvements in OS, PFS with durvalumab after CRT for unresectable disease Feb 15, 2022
Women More Likely to Experience Severe Toxicity of Cancer Treatments Increased risk was particularly pronounced among those receiving immunotherapy Feb 14, 2022
Dual HER2 Therapy Active in Previously Treated Lung Cancer Disease control in 87% of HER2-mutant NSCLC treated with trastuzumab, pertuzumab, docetaxel Jan 27, 2022
Bevacizumab Add-On No Help in Progressive EGFR-Mutant Lung Cancer Single-agent osimertinib prevails in progressive, T790M-positive NSCLC Dec 02, 2021
Tumor Volume-Adapted RT Leads to Good Lung Cancer Control With Low Toxicity No recurrence at 1 year in 90% of cases with primary tumors, metastases, synchronous disease Nov 02, 2021
Targeted RT Boosts PFS in Oligoprogressive Lung Cancer Fivefold improvement in NSCLC but no benefit in oligoprogressive breast cancer Oct 25, 2021
'You're Still Doing WHAT After Lung Cancer Surgery?!' But don't give up on hardened smokers, researcher urges Oct 19, 2021
Newly Approved EGFR Drug Yields Meaningful Benefit in Rare NSCLCs Oral tyrosine kinase inhibitor may serve patient population with high unmet need Oct 14, 2021
Immunotherapy Combo Fails to Boost Survival in Limited-Disease SCLC No PFS or OS improvement with consolidation nivolumab-ipilimumab after standard treatment Sep 29, 2021
Radiation or Surgery in Early Lung Cancer: Does It Make a Difference? Ablative radiation still noninferior to VATS after longer follow-up Sep 24, 2021
How Many Deaths Will New Cigarette Warnings Prevent? Modeling study comes up with big numbers Sep 24, 2021
Top Science From the World Conference on Lung Cancer In this podcast, we examine some of the most important studies presented at this year's meeting Sep 23, 2021 podcast
Another Possible Option for HER2-Mutated Non-Small Cell Lung Cancer More than half of patients responded to antibody-drug conjugate targeting HER2 Sep 19, 2021
More Help on the Way for Lung Cancers With Exon 20 Mutations? Early trials of DZD9008 demonstrated responses in over a third of patients Sep 15, 2021
Cancer Vaccine May Boost Anti-EGFR Efficacy in Non-Small Cell Lung Cancer More than 90% disease control rate, hint of improved PFS in pilot trial Sep 14, 2021
Novel ADC Promising in Certain Non-Squamous Lung Cancers Response rate topped 50% in patients with EGFR wild-type tumors and high MET expression Sep 14, 2021
More Data in Support of Surgery for Malignant Pleural Mesothelioma Six-month improvement in overall survival with surgery plus chemotherapy versus chemo alone Sep 13, 2021
Meta-Analysis Confirms Benefits of Low-Dose CT Screening for Lung Cancer LDCT associated with a 16% relative reduction in mortality versus no screening Sep 13, 2021
Immuno-Oncology Combo Active in Recurrent EGFR/ALK Positive NSCLC Responses in 42% of EGFR group, limited activity in ALK-rearranged lung cancer Sep 12, 2021
Triplet Therapy Proves Safe in Resectable Malignant Pleural Mesothelioma Atezolizumab add-on offers promising outcomes in phase I trial Sep 12, 2021
Durable Response with Immunotherapy Combos in NSCLC with Brain Metastases Analysis of CheckMate 9LA data and phase II study from Spain offer hope in advanced disease Sep 12, 2021
Dual Immunotherapy Boosts Survival in Metastatic NSCLC Benefit with durvalumab-tremelimumab may vary by PD-L1 expression, histology Sep 10, 2021
Study Sheds Light on Physician-Assisted Suicide in Lung Cancer Patients Patients often did not consult with radiation or medical oncologists Sep 09, 2021
Second-Line Combo Fails to Improve Survival in SCLC No OS difference, but lurbinectedin-doxorubicin was less toxic than standard chemotherapy options Sep 09, 2021
High Response Rate in Non-Small Cell Lung Cancer With RET Inhibitor Responses in 66-80% of patients from China confirm activity of pralsetinib Sep 09, 2021
TROP2 Antibody-Drug Conjugate Shows Promise in Lung Cancer Disease control observed in over two-thirds of patients at selected dose Sep 08, 2021
Another Ivermectin Flop; 'Instant' Lung Cancer Decision Tool; Triple COPD Tx & Death Highlights from the European Respiratory Society virtual meeting Sep 08, 2021
No Survival Bump With PARP Inhibitor in Squamous NSCLC Possible benefit in tumors with positive lung cancer-specific gene panel Sep 07, 2021
Negative Trials Close the Book on Once-Promising SCLC Drug Poor tolerability doomed rovalpituzumab tesirine regimens in four clinical trials Sep 07, 2021
AI Blood Test Proves Useful in Lung Cancer Detection Such an approach would be useful considering the barriers to LDCT among high-risk people Aug 25, 2021
Avoiding Hippocampus in Brain RT May Help Preserve Cognitive Function Recall metrics favored hippocampal avoidance at all time points, with no increase in brain mets Aug 13, 2021
Drug Combo Promising in Rare Mesothelioma Small study showed "robust and durable" responses, with "meaningful prolongation of survival" Jul 19, 2021
